Advertisement

Infection

, Volume 42, Issue 3, pp 529–534 | Cite as

First documented outbreak of KPC-2-producing Klebsiella pneumoniae in Switzerland: infection control measures and clinical management

  • E. Lemmenmeier
  • P. Kohler
  • T. Bruderer
  • D. Goldenberger
  • G.-R. Kleger
  • M. Schlegel
Brief Report

Abstract

We report the epidemiological and clinical features of the first outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) type 2 in Switzerland. The outbreak took place in the medical intensive care unit (MICU) of our tertiary care hospital and affected three severely ill patients. After the implementation of strict infection control measures, no further patients colonised with KPC-KP could be detected by the screening of exposed patients. Successful treatment of patients infected with KPC-KP consisted of a combination therapy of meropenem, colistin and tigecycline.

Keywords

Carbapenem-resistant Enterobacteriaceae (CRE) KPC Klebsiella pneumoniae Outbreak Switzerland Infection control 

Notes

Acknowledgements

The authors would like to thank Lauren Clack for the language support.

Conflict of interest

There was no financial support and the authors have no potential conflicts of interest to declare.

Ethical approval

No formal informed consent was obtained from the patients, as this evaluation was considered to be within the context of the overall quality control system instituted at the hospital.

References

  1. 1.
    Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18:413–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–8.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–61.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Giani T, Pini B, Arena F, Conte V, Bracco S, Migliavacca R, et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill. 2013;18. pii: 20489.Google Scholar
  5. 5.
    Giani T, D’Andrea MM, Pecile P, Borgianni L, Nicoletti P, Tonelli F, et al. Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 Carbapenemase. J Clin Microbiol. 2009;47:3793–4.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Cuzon G, Naas T, Demachy M-C, Nordmann P. Nosocomial outbreak of Klebsiella pneumoniae harbouring bla(KPC-3) in France subsequent to a patient transfer from Italy. Int J Antimicrob Agents. 2012;39:448–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Schweizerisches Zentrum für Antibiotikaresistenzen, anresis.ch. http://www.anresis.ch/de/index.html. Accessed 24 July 2013.
  8. 8.
    Poirel L, Lienhard R, Potron A, Malinverni R, Siegrist HH, Nordmann P. Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in a Klebsiella pneumoniae isolate from Switzerland. J Antimicrob Chemother. 2011;66:675–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Babouee B, Widmer AF, Dubuis O, Ciardo D, Droz S, Betsch BY, et al. Emergence of four cases of KPC-2 and KPC-3-carrying Klebsiella pneumoniae introduced to Switzerland, 2009–10. Euro Surveill. 2011;16. pii: 19817.Google Scholar
  10. 10.
    Witteck A, Rettenmund G, Schlegel M. MRSA admission screening in a low prevalence setting—much ado about nothing? Swiss Med Wkly. 2011;141:w13217.PubMedGoogle Scholar
  11. 11.
    Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of clinical microbiology. 9th ed. Washington, DC: ASM Press; 2007.Google Scholar
  12. 12.
    Isenberg HD. Clinical microbiology procedures handbook. 2nd ed. Washington, DC: ASM Press; 2004.Google Scholar
  13. 13.
    Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement (M100-S22). CLSI, Wayne, PA; 2012.Google Scholar
  14. 14.
    Babouee B, Frei R, Schultheiss E, Widmer AF, Goldenberger D. Comparison of the DiversiLab repetitive element PCR system with spa typing and pulsed-field gel electrophoresis for clonal characterization of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2011;49:1549–55.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    ECDC risk assessment on the spread of carbapenemase-producing enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/risk_assessment_CPE.aspx. Accessed 3 July 2013.
  16. 16.
    WHO guidelines on hand hygiene in health care: first global patient safety challenge clean care is safer care. Geneva: World Health Organization; 2009. http://www.ncbi.nlm.nih.gov/books/NBK144013/. Accessed 24 July 2013.
  17. 17.
    Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439–48.PubMedCrossRefGoogle Scholar
  18. 18.
    Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16:112–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260–8.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, et al. Infections acquired by adults who receive extracorporeal membrane oxygenation: risk factors and outcome. Infect Control Hosp Epidemiol. 2013;34:24–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012;56:3395–8.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Le J, McKee B, Srisupha-Olarn W, Burgess DS. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res. 2011;3:106–10.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob. 2012;11:32.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–13.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case–control study. Crit Care Med. 2008;36:807–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • E. Lemmenmeier
    • 1
  • P. Kohler
    • 2
  • T. Bruderer
    • 3
  • D. Goldenberger
    • 4
  • G.-R. Kleger
    • 2
  • M. Schlegel
    • 1
  1. 1.Division of Infectious Diseases and Infection Control, Department of Internal MedicineCantonal Hospital St. GallenSt. GallenSwitzerland
  2. 2.Medical Intensive Care UnitCantonal Hospital St. GallenSt. GallenSwitzerland
  3. 3.Department of Bacteriology, Mycology and ParasitologyCenter of Laboratory Medicine St. GallenSt. GallenSwitzerland
  4. 4.Laboratory of Clinical MicrobiologyUniversity Hospital BaselBaselSwitzerland

Personalised recommendations